Welcome to our dedicated page for Caredx SEC filings (Ticker: CDNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reading CareDx’s biotech-heavy disclosures often feels like decoding genomic sequences. Revenue tied to AlloSure testing, shifts in Medicare reimbursement, and R&D outlays for precision transplant diagnostics are scattered across multiple forms. Stock Titan delivers CareDx SEC filings explained simply, turning a 300-page document into a clear roadmap of growth drivers. Start with the CareDx annual report 10-K simplified to grasp long-term strategy, risk factors, and segment data without wading through dense technical jargon.
Need fast, decisive updates? Each CareDx quarterly earnings report 10-Q filing lands here within seconds of EDGAR release, accompanied by AI-powered summaries that highlight dd-cfDNA test volumes, gross margin trends, and pipeline investment. Real-time alerts surface CareDx Form 4 insider transactions real-time, so you can track when leadership buys or sells shares. Our AI also unpacks every CareDx 8-K material events explained, from new CMS coverage decisions to licensing agreements, ensuring no material development slips past you.
The result is a single destination that answers investors’ toughest questions: How are Medicare billing codes shaping cash flow? What do CareDx executive stock transactions Form 4 signal ahead of trial read-outs? Where is the board setting pay in the CareDx proxy statement executive compensation? With understanding CareDx SEC documents with AI, you receive concise risk commentary, comparable tables, and forward-looking indicators. Whether performing a CareDx earnings report filing analysis or scanning CareDx insider trading Form 4 transactions, our expert annotations and real-time feed provide the clarity and speed required to act confidently.
CareDx insider grant reported: Nathan Smith, identified as Chief Financial Officer, acquired 42,000 restricted stock units (RSUs) on 08/07/2025, increasing his direct beneficial ownership to 42,000 shares. Each RSU is a contingent right to receive one share of the company's common stock upon settlement for no consideration. The RSUs vest over time: 25% of the total vests on August 7, 2026, with 1/16th of the total vesting in quarterly installments thereafter until fully vested, subject to continued service. No derivative securities were reported in Table II.
FAQ
What is the current stock price of Caredx (CDNA)?
What is the market cap of Caredx (CDNA)?
